Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

Share Price is delayed by 15 minutes
Get Live Data
1.715    0.025 (1.48%)
Bid:
1.50
Ask:
1.93
Spread: 0.43 (28.667%)
Market Cap: £5.93m
PRM Live PriceLast checked at - London Stock Exchange

Intraday Proteome Share Chart

Director's Dealing

25 Jul 2007 12:03

Proteome Sciences Plc ("Proteome Sciences" or "the Company")

DIRECTOR'S DEALING

Proteome Sciences announces that it has received notification today from James Malthouse, an Executive Director of the Company, that 50,000 ordinary shares that were held in his late wife's name have been transferred for a nil consideration to his adult daughter. As a consequence of this, the shares no longer form part of his beneficial holdings as defined by the AIM rules.

James Malthouse now has an interest in 250,000 Ordinary Shares of the issued ordinary share capital of the Company.

Enquiries Proteome Sciences plc

Christopher Pearce, Chief Executive Officer

Email: christopher.pearce@proteomics.com

James Malthouse, Finance Director

Email: james.malthouse@proteomics.com

Tel: +44 (0)1932 865065

Public Relations for Proteome Sciences

IKON AssociatesAdrian Shaw Tel: +44 (0)1483 535102Mobile: +44 (0)797 9900733Email: adrian@ikonassociates.com Coast CommunicationsMatt BaldwinTel: +44 (0) 1233 503200Mobile: +44 (0) 7930 439739

Email: matt@coastcommunications.com

PROTEOME SCIENCES PLC
Date   Source Headline
19th Nov 20145:08 pmRNSHolding(s) in Company
12th Nov 20147:00 amRNSTrading Update
16th Oct 20147:00 amRNSDirectorate Change
1st Oct 20143:54 pmRNSDirector/PDMR Shareholding
30th Sep 20147:01 amRNSBlocklisting Interim Review
30th Sep 20147:00 amRNSDirectorate Change
30th Sep 20147:00 amRNSHalf Yearly Report
26th Sep 20147:00 amRNSCK1d Update: Toxicity Results
25th Sep 201410:08 amRNSContract with Genting TauRx Diagnostic Centre
15th Sep 20147:00 amRNSScience and Technology Award
19th Aug 20147:00 amRNSAppointment of Joint Broker
8th Jul 20145:45 pmRNSDirector/PDMR Shareholding
8th Jul 20147:00 amRNSAlzheimer's blood test study
1st Jul 20147:00 amRNSDirectorate Change
30th Jun 20144:42 pmRNSResult of AGM
9th Jun 20144:18 pmRNSAnnual Financial Report
29th May 20147:00 amRNSPreliminary results
1st Apr 20147:00 amRNSBlocklisting Interim Review
27th Mar 20147:00 amRNSPancreatic Cancer Study in PLOS ONE
3rd Mar 20144:25 pmRNSDirectorate Change
28th Feb 20143:46 pmRNSHolding(s) in Company
24th Feb 20147:00 amRNSPlacing
7th Feb 20147:00 amRNSTrading Update
3rd Feb 20144:44 pmRNSHolding(s) in Company
27th Dec 20134:35 pmRNSPrice Monitoring Extension
4th Dec 20137:00 amRNSTrading Update
20th Nov 20137:00 amRNSPatient Stratification Biomarkers for Liver Cancer
6th Nov 20132:51 pmRNSHolding(s) in Company
1st Oct 201310:34 amRNSBlocklisting Interim Review
30th Sep 20137:00 amRNSHalf Yearly Report
18th Sep 20132:00 pmRNSKey Assay Development at HUPO
2nd Sep 201312:12 pmRNSHolding(s) in Company
6th Aug 201312:36 pmRNSIssue of Equity
18th Jul 20137:00 amRNSNew Data Shows CK1d Blocks Tau in AD Model
28th Jun 20131:00 pmRNSAGM Statement
28th Jun 20137:00 amRNSPatent Statement
26th Jun 20139:27 amRNSHolding(s) in Company
12th Jun 20137:00 amRNSMajor technology contract
5th Jun 20134:08 pmRNSAnnual Financial Report
30th May 20137:01 amRNSPreliminary Results
19th Apr 20137:00 amRNSTrading Update
2nd Apr 20137:00 amRNSBlock admission return
18th Mar 20137:00 amRNSDevelopments in Alzheimer's Disease
22nd Jan 20137:00 amRNSTrading Statement
31st Dec 20127:00 amRNSCK1D Update
3rd Dec 201211:06 amRNSHolding(s) in Company
28th Sep 20127:00 amRNSHalf Yearly Report
18th Sep 20124:04 pmRNSBlock Admission Return
18th Sep 20124:01 pmRNSBlock Admission Return
18th Sep 20127:00 amRNSFurther re. University of Geneva Study

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.